Trial Profile
Safety and efficacy of apixaban and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation for secondary prevention of stroke of systemic embolism
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jun 2017
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Rivaroxaban (Primary) ; Warfarin
- Indications Embolism; Stroke
- Focus Adverse reactions; Therapeutic Use
- 30 Jun 2017 New trial record